A groundbreaking new drug, currently identified as VERVE-102, is poised to revolutionize the treatment of high cholesterol levels, potentially offering a one-off solution that could last a lifetime. This innovative therapy operates by genetically switching off a specific gene responsible for the production of low-density lipoprotein (LDL), often referred to as 'bad' cholesterol. Initial findings from a small-scale trial involving 14 patients, who were already on cholesterol-lowering medication but still had high LDL levels, demonstrated remarkable efficacy: a single infusion reduced their LDL levels by up to 53 percent in just four weeks.

High cholesterol is a pervasive health concern, with the British Heart Foundation estimating that approximately half of all adults in the UK have elevated levels. A total cholesterol reading should ideally be below 5mmol/L, and non-HDL cholesterol below 4mmol/L. An accumulation of 'bad' LDL cholesterol significantly increases the risk of serious cardiovascular events, such as heart attacks and strokes, as it leads to the narrowing and hardening of arteries, potentially causing blockages and ruptures.

Currently, the primary treatment for high cholesterol involves statins, which work by inhibiting a liver enzyme essential for LDL production. Around seven million people in the UK rely on statins, which are generally very effective, capable of reducing LDL levels by up to 50 percent. However, statins are not without their drawbacks; some patients report side effects like muscle pain and weakness, leading more than half to discontinue treatment within a year. Despite these concerns, experts like Professor Louise Bowman from the University of Oxford affirm statins' proven efficacy, safety, and general tolerability over many years of extensive trials.

More recently, a class of drugs known as PCSK9 inhibitors, including alirocumab and evolocumab, has emerged. Unlike statins, these drugs facilitate the body's natural process of clearing LDL from the bloodstream and returning it to the liver for breakdown. PCSK9 is a liver protein that normally impedes this clearing process, allowing LDL to accumulate. Licensed in the UK since 2015, PCSK9 inhibitors are administered via injections, some every few weeks, others like inclisiran, every six months. Studies indicate they can reduce LDL levels by up to 55 percent, and when combined with statins, achieve an overall reduction of up to 70 percent. Despite their effectiveness, PCSK9 inhibitors are considerably more expensive than statins, costing around £3,000 annually compared to as little as £20 for statins, making them typically reserved for patients with familial hypercholesterolemia.

VERVE-102, the experimental one-off treatment, also targets the PCSK9 protein but does so by switching off the gene that instructs liver cells to produce it. Administered as a slow intravenous infusion, this gene-editing approach does not entirely eliminate LDL production, as PCSK9 is just one of several mechanisms regulating LDL in the liver. Nevertheless, the recent trial demonstrated significant reductions: a 21 percent decrease in LDL at its lowest dose and a 53 percent decrease at its highest dose, all within a month of treatment. Initial data also suggest a minimal incidence of serious adverse effects.

Dr. Ricardo Petraco, a consultant cardiologist, likens our genes to a recipe book, continuously producing proteins with specific functions. He explains that VERVE-102 precisely modifies a single compound within the PCSK9 gene, causing a 'malfunction in its recipe' to halt LDL production. While expressing immense optimism, Dr. Petraco emphasizes the critical need for more extensive data to confirm long-term safety, stating, "There is an element of the unknown with gene therapy and long-term follow-up studies are essential." He cautiously adds that if VERVE-102 proves safe and effective in larger trials, it could indeed be a 'gamechanger'.

A larger global trial is planned, potentially using higher doses, and is expected to recruit individuals with familial hypercholesterolemia. Ultimately, VERVE-102 could benefit a broader population, including those resistant to current drugs or unable to tolerate their side effects. Professor David Middleton highlights the likely high cost of such gene-editing drugs, contrasting them with the inexpensive and effective statins. However, Professor Bowman points out the immense potential of genetically switching off the mechanism that causes cholesterol to rise for good, particularly appealing to patients who dislike daily tablets or regular injections. If proven effective and safe, VERVE-102 represents a truly significant advancement for the future of cardiovascular health.